Latest Breaking News On - Ji xing pharmaceuticals - Page 9 : comparemela.com

Milestone Pharmaceuticals Announces Exclusive License Agreement with Ji Xing Pharmaceuticals to Develop and Commercialize Etripamil for PSVT in Greater China

Milestone Pharmaceuticals Announces Exclusive License Agreement with Ji Xing Pharmaceuticals to Develop and Commercialize Etripamil for PSVT in Greater China - Ji Xing Pharmaceuticals to develop and commercialize etripamil for patients with PSVT in Greater China - - Milestone to receive a $15 million upfront cash payment and a $5 million equity investment by RTW Investments, LP - News provided by Share this article Share this article MONTREAL and CHARLOTTE, N.C., May 17, 2021 /PRNewswire/ Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced an exclusive license and collaboration agreement with Ji Xing Pharmaceuticals (Ji Xing) to develop and, if approved, commercialize the investigational drug etripamil in patients with paroxysmal supraventricular tachycardia (PSVT) and additional cardiovascular conditions in Greater China. Ji Xing is a biotechno

Ji xingUnited statesPeter fongDavid pittsJoseph olivetoMilestone pharmaceuticals incCompany on twitter at milestonepharmaJi xing pharmaceuticalsPrnewswire milestone pharmaceuticals incExchange commissionHead of company creationMilestone pharmaceuticalsChief executive officerCompany creationNew york basedPrivate securities litigation reform act

Milestone Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Clinical, Regulatory, and Corporate Update

Milestone Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Clinical, Regulatory, and Corporate Update News provided by Share this article Share this article MONTREAL and CHARLOTTE, N.C., May 17, 2021 /PRNewswire/ Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today reported financial results for the first quarter ended March 31, 2021 and provided a clinical, regulatory, and corporate update. We continue to work closely with our existing clinical trial sites, as well as add new sites, to address the impact that the COVID-19 pandemic has had on patient enrollment in the pivotal Phase 3 RAPID trial of etripamil in patients with PSVT. While we are encouraged by recent improvements in enrollment rates, we now expect to report topline data from the RAPID trial in the second half of 2022, said Joseph Oliveto, President and Chief Executiv

United statesJi xingDavid pittsJoseph olivetoBruce stamblerMontreal heart instituteCompany on twitter at milestonepharmaPrnewswire milestone pharmaceuticals incJi xing pharmaceuticals toCenters for diseaseMilestone pharmaceuticals incAmerican college of cardiologyPiedmont heart instituteDrug administrationJi xing pharmaceuticalsCompany expects to report topline data

(MIST) - Milestone Pharma-Ji Xing Pharma Ink $127M Etripamil Development Agreement For China

(MIST) - Milestone Pharma-Ji Xing Pharma Ink $127M Etripamil Development Agreement For China
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.

Ji xingMilestone pharmaceuticals incJi xing pharmaceuticalsPrice actionஜி க்ஷிங்மைல்கல் மருந்துகள் இன்க்ஜி க்ஷிங் மருந்துகள்ப்ரைஸ் நடவடிக்கை

Cytokinetics Inc (CYTK) Q1 2021 Earnings Call Transcript

Operator Good afternoon, and welcome, ladies and gentlemen, to Cytokinetics First Quarter 2021 Conference Call. At this time, I would like to inform you that this call is being recorded and that all participants are in a listen-only mode. At the company s request, we will open the call for questions-and-answers after the presentation. I will now like to turn the call over to Diane Weiser, Cytokinetics Senior Vice President of Corporate Communications and Investor Relations. Please go ahead. Diane Weiser Senior Vice President of Corporate Communications & Investor Relations Good afternoon, and thanks for joining us on the call today. Robert Blum, our President and Chief Executive Officer, will kick off the call with an overview of the quarter and recent developments. Then Fady Malik, our EVP of Research and Development, will provide an update on omecamtiv mecarbil, including progress following a recent meeting with FDA and what to expect from upcoming analyses from GALACTIC-H

United statesJi xingMorgan stanleySalim syed mizuhoStuart kupferRobert wongCharles duncanCharles duncan cantor fitzgeraldTed tentoffFady malikAndrew callosTed tentoff piper sandlerJohn teerlinkSalim syedPiper sandlerDiane weiser

Cytokinetics Inc (CYTK) Q4 2020 Earnings Call Transcript

Cytokinetics Inc (CYTK) Q4 2020 Earnings Call Transcript Motley Fool Transcribers © The Motley Fool Logo of jester cap with thought bubble. Cytokinetics Inc (NASDAQ: CYTK) Operator Good afternoon, and welcome, ladies and gentlemen, to Cytokinetics Fourth Quarter 2020 Conference Call. [Operator Instructions] I will now turn the call over to Diane Weiser, Cytokinetics Senior Vice President of Corporate Creations and Investor Relations. Please go ahead. This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company s SEC filings. Please see our

Ji xingUnited statesMorgan stanleyRaymond jamesSalim syed mizuhoStuart kupferCharles duncanRobert wongCharles duncan cantor fitzgeraldMuna bhanjiCarter gouldNancy wysenskiGreg suvannavejhCarter gould barclaysMike felkerTed tentoff